Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting

2024-04-24 11:32:00

Presentation of industry-leading T-cell delivery in NHPs

Oral presentation highlighting an all-RNA system enabling exon-sized genome insertions

CAMBRIDGE, Mass.--()--ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicinestoday announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland.

“We are excited to highlight foundational research and development advancements at ASGCT supported by our poster presentation illuminating ReNAgade’s continued work in validating our immune tropic LNP-based delivery systems in NHPs with broad potential applications in oncology and autoimmune diseases,” said Pete Smith, Ph.D., Chief Scientific Officer of ReNAgade. “Additionally, our oral presentation demonstrates a non-viral, all-RNA gene editing system enabling in vivo, exon-sized insertion and probable re-dosing with the goal of higher specificity and a better safety profile when used in the clinical setting. Together, these promising data are another important step in our efforts to innovate beyond the current limitations of RNA medicine.”

Key Highlights from the Abstracts:

  • Employed a systematic barcoding screening approach to evaluate and identify engineered lipid nanoparticles (LNP) from a library of 200+ LNPs across multiple structural and chemically distinct classes of ionizable, helper, structural, and hydrophilic lipids. Lead LNP candidate demonstrated ~60% delivery efficiency in total splenic T cells and ~80% delivery efficiency in peripheral blood T cells in non-human primate models.
  • Improved retron-mediated target insertion through a combination of retron reverse transcriptase (RT) engineering, non-coding RNA (ncRNA) minimization, chemical modification, and homology-dependent repair manipulation. Combination of retron system optimization and ncRNA engineering led to 2-fold higher 305 base pair insertion and ~40% editing efficiency in hematopoietic stem cells.

ASGCT Annual Meeting Presentation Details:

  • TITLE: “Retron Mediated Exon-Sized Genome Insertion Using an All-RNA System”

SESSION TITLE: New Technologies for Gene Targeting and Gene Correction
PRESENTATION TYPE: Oral
ABSTRACT NUMBER: 14
PRESENTER: Inna Shcherbakova, Ph.D., Senior Director, Platform, ReNAgade Therapeutics
DATE AND TIME: Tuesday, May 7, 2024, from 2:15 p.m. - 3:30 p.m. ET

  • TITLE: “Novel Immune Tropic LNP-Based mRNA Delivery in Non-Human Primates”

SESSION TITLE: Wednesday Posters: Other Nonviral Delivery
PRESENTATION TYPE: Poster
ABSTRACT NUMBER: 749
PRESENTER: Juliet Crabtree, Ph.D., Associate Principal Scientist, ReNAgade Therapeutics
DATE AND TIME: Wednesday, May 8, 2024, at 12:00 p.m. ET

About ReNAgade Therapeutics

ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.

To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.

ReNAgade Therapeutics—RNA Without Limits

For more information about the company, its technologies, and its leadership, visit www.renagadetx.com.

Contacts

Investor Relations Contact:
Emily Brabbit, Argot Partners
(212) 600-1902
renagade@argotpartners.com

Media Relations Contact:
Sarah Sutton, Argot Partners
(212) 600-1902
renagade@argotpartners.com

Link

Interfax Business Wire

2024-05-28
17:07:00
Intelsat Multi-Orbit Inflight Connectivity Coming to Japan Airlines
11:13:00
The Digital Cooperation Organization Launches “EconomiX” Magazine to Enhance Knowledge Sharing in the Digital Ecosystem
11:10:00
HEINEKEN Teams Up With Blue Yonder To Improve Demand Planning
10:59:00
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
10:21:00
WETEX 2024 Receives Applications for Participants and Exhibitors From All Over the World
2024-05-27
15:23:00
Resorts World Cruises Becomes First Asian Cruise Line to Deploy Integrated MEO-LEO Service from SES
10:54:00
Scottish Sensor Technology Startup Novosound Targets Expansion in APAC
10:50:00
SLB OneSubsea Awarded Contract for Phase 3, Stage 2 of Equinor’s North Sea Troll Project
10:45:00
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
10:38:00
Canva Unveils Enterprise Era With Powerful New Workplace Products Debuted at Canva Create
09:42:00
AXON Aviation Group transfers business aircraft division to Jetcraft
2024-05-24
16:16:00
WORLD’S MOST ICONIC ROCK BAND, THE ROLLING STONES, SELECTS THUNDER RIDGE NATURE ARENA AS DESTINATION FOR FINAL NORTH AMERICAN PERFORMANCE
15:55:00
Enter the Dragon Boat: Hong Kong International Dragon Boat Races Return in June
15:50:00
NTT and NTT DATA Roar into the Indianapolis 500 with AI-powered Fan Experience
15:47:00
Celltrion receives European Commission approval of Omlyclo® (CT-P39), the first and only omalizumab biosimilar approved in Europe
15:44:00
Mary Kay Awards Grants to Five Aspiring Young Scientists at Regeneron International Science and Engineering Fair
11:09:00
Enhanced Experian Ascend Technology Platform™ Transforms Software for Credit, Fraud and Analytics
10:52:00
Dutch Web3 Startup Klayr Labs Launches to Takeover the Layer 1 Platform of Lisk
10:50:00
Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
10:46:00
Lenovo Group: Q4 and Full Year Financial Results 2023/24
Back to Top